FOP Phase III MOVE Trial
|DESCRIPTION||A Phase III, multicenter, single treatment arm study evaluating the safety and efficacy of palovarotene for the treatment of FOP.|
|ELIGIBILITY CRITERIA||Participants must:
|DESIGN||We intend to enroll 80 participants. All participants will take palovarotene daily for 24 months, with increased dosing in the event of a flare up.
Participants are required to visit the clinical site at enrollment, and at months 6, 12, 18 and 24 during which they will undergo WBCT scans and other assessments. Safety assessments will be performed at months 3, 9, 15 and 21 at the participant’s home.
|TRIAL ID NUMBER||PVO-1A-301|
|CONTACT CLEMENTIA||To contact Clementia for more information on the MOVE study, please click here.|